Jim Brandon
About Jim Brandon
Jim Brandon is the Regional Business Director for the Southwest at Deciphera Pharmaceuticals, a position he has held since 2019. He has extensive experience in the pharmaceutical industry, having worked in various roles at Genentech for over a decade.
Work at Deciphera Pharmaceuticals
Jim Brandon has served as the Regional Business Director for the Southwest at Deciphera Pharmaceuticals since 2019. In this role, he is responsible for overseeing business operations and driving sales strategies within the region. His experience in the pharmaceutical industry contributes to the company's objectives in delivering innovative therapies.
Experience at Genentech
Jim Brandon has extensive experience at Genentech, where he held multiple positions over a span of several years. He worked as a Senior Division Manager for Cancer Immunotherapy from 2018 to 2019 in Dallas, TX. Prior to that, he was the iRegion Sales Director for Cancer Immunotherapy from 2017 to 2018, also in Dallas. His career at Genentech began as a Senior Clinical Specialist in Hematology from 2004 to 2008, followed by various managerial roles, including Division Manager for Lung/GI and Sr. Manager of Field Operations in Hematology.
Education and Expertise
Jim Brandon holds a Master's Degree in Health/Health Care Administration/Management from Saint Louis University. He also earned a Bachelor of Arts in Political Science and Government from the University of Missouri-Columbia. His educational background provides a solid foundation for his roles in the pharmaceutical industry, particularly in management and operations.
Career Timeline
Jim Brandon's career spans over a decade in the pharmaceutical sector, primarily with Genentech. He transitioned through various roles, starting as a Senior Clinical Specialist in Hematology and advancing to senior management positions. His roles included Region Program Manager for Hematology, Division Manager for Cancer Immunotherapy, and Sr. Manager of Field Operations. His current position at Deciphera Pharmaceuticals marks a continuation of his leadership in the industry.